fosaprepitant Emend IV
Selected indexed studies
- Cyclic vomiting syndrome. (Brain Dev, 2026) [PMID:41719916]
- Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis. (Adv Ther, 2020) [PMID:32447650]
- Aprepitant and fosaprepitant drug interactions: a systematic review. (Br J Clin Pharmacol, 2017) [PMID:28470980]
_Worker-drafted node — pending editorial review._
Connections
fosaprepitant Emend IV is a side effect of
Sources
- Aprepitant and fosaprepitant drug interactions: a systematic review. (2017) pubmed
- Cyclic vomiting syndrome. (2026) pubmed
- Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis. (2020) pubmed
- Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation. (2018) pubmed
- Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting. (2018) pubmed
- Aprepitant: Review on Solubility Enhancement. (2025) pubmed
- Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting. (2025) pubmed
- Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects. (2009) pubmed
- A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis. (2013) pubmed
- Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602). (2023) pubmed